IMMUTACE: A biomarker-orientated phase II, single-arm, open-label AIO   study of transarterial chemoembolization (TACE) in combination with   nivolumab performed for intermediate-stage hepatocellular carcinoma   (HCC; AIO-HEP-0217)-Updated efficacy results.

Title:: IMMUTACE: A biomarker-orientated phase II, single-arm, open-label AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma (HCC; AIO-HEP-0217)-Updated efficacy results.
Document type:: Meeting Abstract
Author(s):: Saborowski, Anna; Waldschmidt, Dirk; Hinrichs, Jan; Ettrich, Thomas Jens; Martens, Uwe Marc; Mekolli, Ardian; De Toni, Enrico N.; Berg, Thomas; Geissler, Michael; Hausner, Guido; Maenz, Martin; Ehmer, Ursula; Kirstein, Marta; Vogel, Arndt
Journal title abbreviation:: J Clin Oncol
Year:: 2022
Journal volume:: 40 Suppl S
Journal issue:: 16
Print-ISSN:: 0732-183X
TUM Institution:: Klinik und Poliklinik für Innere Medizin II, Gastroenterologie
BibTeX

Occurrences: